Antiviral immunotropic agent for the treatment of acute respiratory viral infections
Inventors
CHERTORIZHSKY, Evgeny Alexandrovich • Ovchinnikov, Mikhail Vladimirovich • Kleimenov, Aleksey Viktorovich
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
The proposed methods of treatment pertain to medicine, in particular pharmacology, and concerns the application of a nasal medicinal composition containing hexapeptide tyrosyl-D-alanyl-glycyl-phenylalanyl-leucyl-arginine or its pharmaceutically acceptable salt for the treatment of acute respiratory viral infections (ARVIs), in particular those caused by the influenza virus.
Core Innovation
The disclosed method concerns intranasal administration of a nasal medicinal composition containing the hexapeptide tyrosyl-D-alanyl-glycyl-phenylalanyl-leucyl-arginine, or a pharmaceutically acceptable salt, to stimulate phagocytosis by neutrophils and macrophages and production of endogenous interferons during treatment of acute respiratory viral diseases. The supplied summary also describes direct antiviral and immunomodulating effects, including use in relation to influenza.
The reported preclinical findings include inhibition of influenza virus and suppression of adenovirus cytopathic effects, alongside increased interferon-α production, phagocytic activity, and natural-killer-cell cytotoxicity. The summary also reports improved survival in influenza-infected mice and reduced pro-inflammatory cytokine production. The partial content does not provide the background section; therefore, the problem identified in that section is not explicitly described in patent.
Claims Coverage
The provided claims identify one independent claim featuring one inventive feature.
Intranasal stimulation of phagocytosis and endogenous interferon production
The independent claim covers intranasally administering a nasal medicinal composition comprising the specified hexapeptide or a pharmaceutically acceptable salt to stimulate phagocytosis of neutrophils and macrophages and production of endogenous interferons during treatment of acute respiratory viral diseases.
The independent claim centers on the intranasal use of the specified hexapeptide or its pharmaceutically acceptable salt to stimulate phagocytosis and endogenous interferon production during treatment of acute respiratory viral diseases.
Stated Advantages
The summary reports direct antiviral and immunomodulating effects, including inhibition of influenza virus and suppression of adenovirus cytopathic effects.
The reported preclinical findings include improved survival in influenza-infected mice, increased interferon-α production and phagocytic activity, enhanced natural-killer-cell cytotoxicity, and reduced pro-inflammatory cytokine production.
Documented Applications
Intranasal treatment of acute respiratory viral diseases, including influenza.
Interested in licensing this patent?